Regency Capital Management Inc. DE Sells 57,887 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Regency Capital Management Inc. DE lessened its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 8.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 609,424 shares of the company's stock after selling 57,887 shares during the period. Aura Biosciences comprises 2.7% of Regency Capital Management Inc. DE's investment portfolio, making the stock its 15th largest holding. Regency Capital Management Inc. DE owned about 1.22% of Aura Biosciences worth $5,009,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. American Century Companies Inc. purchased a new stake in shares of Aura Biosciences during the second quarter worth $119,000. SG Americas Securities LLC bought a new position in Aura Biosciences in the 3rd quarter worth $169,000. JPMorgan Chase & Co. boosted its holdings in Aura Biosciences by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company's stock valued at $477,000 after acquiring an additional 27,718 shares during the period. Barclays PLC increased its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company's stock worth $544,000 after purchasing an additional 43,897 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company's stock worth $487,000 after purchasing an additional 8,194 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Stock Down 2.6 %

AURA traded down $0.21 during midday trading on Friday, reaching $7.89. 119,197 shares of the company's stock were exchanged, compared to its average volume of 106,918. The business has a 50-day simple moving average of $8.38 and a two-hundred day simple moving average of $8.93. The firm has a market capitalization of $394.11 million, a price-to-earnings ratio of -4.56 and a beta of 0.30. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.02. As a group, research analysts anticipate that Aura Biosciences, Inc. will post -1.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Scotiabank increased their price objective on Aura Biosciences from $20.00 to $23.00 and gave the company a "sector outperform" rating in a research report on Friday, October 18th. Cowen reaffirmed a "buy" rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research increased their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, October 18th. Finally, HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $23.00.

Insider Buying and Selling

In other news, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now owns 151,693 shares in the company, valued at approximately $1,419,846.48. This represents a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Los Pinos Elisabet De sold 9,200 shares of the firm's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total value of $98,808.00. Following the completion of the sale, the insider now owns 320,647 shares of the company's stock, valued at approximately $3,443,748.78. This trade represents a 2.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,531 shares of company stock worth $345,454 in the last quarter. 5.40% of the stock is owned by corporate insiders.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.